Oxaliplatin-induced neurotoxicity and the development of neuropathy
- PMID: 15880395
- DOI: 10.1002/mus.20340
Oxaliplatin-induced neurotoxicity and the development of neuropathy
Abstract
The pathophysiology of oxaliplatin-induced neurotoxicity remains unclear, although in vitro studies suggest involvement of voltage-gated Na+ channels. In the present study, clinical assessment was combined with nerve conduction studies (NCS) and nerve excitability studies in 16 patients after completion of oxaliplatin therapy. Chronic neuropathic symptoms persisted in 50% of patients. NCS confirmed abnormalities in symptomatic patients: sensory potentials were significantly low, whereas motor studies remained essentially normal. At 12-month follow-up of symptomatic patients, positive sensory symptoms improved but NCS abnormalities persisted. Cumulative oxaliplatin dose was a predictor of neuropathy, and long-term effects appeared to be minimized by low single-infusion dosages. Nerve excitability measures in symptomatic patients established that axons were of high threshold. Refractoriness was significantly greater in patients (symptomatic group, 56.3 +/- 24.9%; entire patient group, 46.3 +/- 12.5%; controls, 27.1 +/- 1.9%; P < 0.05). Thus, although positive sensory symptoms of oxaliplatin-induced neuropathy improved, negative sensory symptoms and abnormalities of sensory nerve conduction persisted. Differences in nerve excitability measures, particularly refractoriness, support in vitro studies indicating involvement of voltage-gated transient Na+-channel dysfunction in the development of oxaliplatin-induced neurotoxicity.
Similar articles
-
Oxaliplatin-induced neurotoxicity: changes in axonal excitability precede development of neuropathy.Brain. 2009 Oct;132(Pt 10):2712-23. doi: 10.1093/brain/awp219. Epub 2009 Sep 10. Brain. 2009. PMID: 19745023
-
Acute abnormalities of sensory nerve function associated with oxaliplatin-induced neurotoxicity.J Clin Oncol. 2009 Mar 10;27(8):1243-9. doi: 10.1200/JCO.2008.19.3425. Epub 2009 Jan 21. J Clin Oncol. 2009. PMID: 19164207
-
Oxaliplatin and axonal Na+ channel function in vivo.Clin Cancer Res. 2006 Aug 1;12(15):4481-4. doi: 10.1158/1078-0432.CCR-06-0694. Clin Cancer Res. 2006. PMID: 16899592
-
Oxaliplatin-associated neuropathy: a review.Ann Pharmacother. 2005 Jan;39(1):128-35. doi: 10.1345/aph.1E319. Epub 2004 Dec 8. Ann Pharmacother. 2005. PMID: 15590869 Review.
-
A review on oxaliplatin-induced peripheral nerve damage.Cancer Treat Rev. 2008 Jun;34(4):368-77. doi: 10.1016/j.ctrv.2008.01.003. Epub 2008 Feb 20. Cancer Treat Rev. 2008. PMID: 18281158 Review.
Cited by
-
An effective therapeutic approach for oxaliplatin-induced peripheral neuropathy using a combination therapy with goshajinkigan and bushi.Cancer Biol Ther. 2016 Nov;17(11):1206-1212. doi: 10.1080/15384047.2016.1210742. Cancer Biol Ther. 2016. PMID: 27416484 Free PMC article.
-
Nerve excitability assessment in chemotherapy-induced neurotoxicity.J Vis Exp. 2012 Apr 26;(62):3439. doi: 10.3791/3439. J Vis Exp. 2012. PMID: 22565594 Free PMC article.
-
[Painful hyperexcitability syndrome with oxaliplatin containing chemotherapy. Clinical features, pathophysiology and therapeutic options].Schmerz. 2008 Feb;22(1):16-23. doi: 10.1007/s00482-007-0552-5. Schmerz. 2008. PMID: 17578604 Review. German.
-
Antibody Conjugated PLGA Nanocarriers and Superparmagnetic Nanoparticles for Targeted Delivery of Oxaliplatin to Cells from Colorectal Carcinoma.Int J Mol Sci. 2022 Jan 21;23(3):1200. doi: 10.3390/ijms23031200. Int J Mol Sci. 2022. PMID: 35163122 Free PMC article.
-
Different apoptotic pathways activated by oxaliplatin in primary astrocytes vs. colo-rectal cancer cells.Int J Mol Sci. 2015 Mar 9;16(3):5386-99. doi: 10.3390/ijms16035386. Int J Mol Sci. 2015. PMID: 25761243 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Medical
